

# Viral Vector and Plasmid DNA: Technologies and Global Markets

<https://marketpublishers.com/r/V1BDE97496CEN.html>

Date: March 2024

Pages: 128

Price: US\$ 5,500.00 (Single User License)

ID: V1BDE97496CEN

## Abstracts

### Report Scope:

The report provides a comprehensive summary of the viral vector and plasmid DNA technologies market focusing cell and gene therapies, along with detailed competitive landscape and profiles of key market players that include revenue, product portfolios and recent activities. The report analyzes trends and dynamics, including drivers, limitations, challenges, and opportunities. This research study discusses historical, current, and potential market size. The report will enable market players and new entrants to make informed decisions about the production and licensing of goods and services. Organizations, distributors, and exporters should find the information about market development and trends useful. The study segments the market on the basis of product type, applications, and end use. Geographical market analysis is provided for all the major segments. The report offers country-level analysis of markets to provide a better understanding of the major segments.

The market is divided into segments and by application/industry as follows:

By product type:

Viral vector.

Plasmid DNA.

By application:

Cancer.

Genetic disorders.

Infectious diseases.

Cardiovascular diseases.

Other diseases.

By end-user:

Research institutes.

Pharmaceutical and biopharmaceutical companies.

Each area is covered in detail, identifying current products in the market in the base year (2022), measuring the current market size and identifying current and potential market drivers, forecasting for 2028, assessing current and potential competitors, and identifying current competitor market shares for 2022.

Report Includes:

93 data tables and 47 additional tables

An overview of the global market for viral vector and plasmid DNA

Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028

Evaluation of the current market size and revenue growth prospects for viral vector and plasmid DNA, along with a market share analysis by product type, application and geographic region

A look at the innovations, technological advances, and product launches from leading companies

Analysis of the industry's regulatory framework and policies, and its product pipeline

Discussion of ESG challenges and ESG practices

Analysis of the key companies' market shares, proprietary technologies, strategic alliances and other market strategies, and patents

Profiles of the leading players in the industry

## Contents

### **CHAPTER 1 EXECUTIVE SUMMARY**

Market Outlook  
Scope of Report  
Market Summary

### **CHAPTER 2 MARKET OVERVIEW**

Viral Technology  
Cell and Gene Therapy

### **CHAPTER 3 MARKET DYNAMICS**

Market Dynamics  
Drivers  
Opportunities  
Restraints  
Challenges

### **CHAPTER 4 EMERGING TECHNOLOGIES AND DEVELOPMENTS**

Overview  
AI in Viral Vector Production  
Doggy Bone DNA  
FRAGment Recycler: A New Technology for Plasmid DNA Synthesis  
Patents  
Patent Holdings by Manufacturer  
Clinical Trials  
Selected Clinical Trials of Viral Vectors and Plasmid DNA Technologies

### **CHAPTER 5 GLOBAL MARKET FOR VIRAL VECTOR AND PLASMID DNA TECHNOLOGIES**

Segmentation Breakdown  
Market Breakdown by Product Type  
Market Breakdown by End User  
Research Institutes

Pharmaceutical and Biopharmaceutical Companies

Market Breakdown by Application

Cancer

Genetic Disorders

Infectious Diseases

Cardiovascular Diseases

Other Diseases

Geographic Breakdown

Market Breakdown by Region

North America

Latin America

Europe

Asia-Pacific

Rest of the World

## **CHAPTER 6 COMPETITIVE INTELLIGENCE**

Industry Scenario

Company Shares

Competitive Landscape among Companies

Competitive Landscape in Viral Vectors

Competitive Landscape in Plasmid DNA

## **CHAPTER 7 SUSTAINABILITY IN THE MARKET FOR VIRAL VECTOR AND PLASMID DNA TECHNOLOGIES: AN ESG PERSPECTIVE**

Introduction

Environmental Factors

Social Factors

Governance Factors

ESG Performance among Major Companies

ESG Performance of Select Companies

Lonza: ESG Performance

Thermo Fisher Scientific: ESG Performance

Conclusion

## **CHAPTER 8 APPENDIX**

Research Methodology

Acronyms

References

Company Profiles

AGILENT TECHNOLOGIES INC.

BLUEBIRD BIO INC.

CATALENT INC.

DANAHER CORP.

FUJIFILM HOLDINGS CORP.

GENSCRIPT

GILEAD SCIENCES INC.

LONZA

NOVARTIS AG

OXFORD BIOMEDICA PLC

PLASMIDFACTORY GMBH

REGENXBIO INC.

THERMO FISHER SCIENTIFIC INC.

VGXI INC.

## List Of Tables

### LIST OF TABLES

Summary Table : Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028

Table 1 : Global Incidence of All Cancers, by WHO Region, 2022-2050

Table 2 : Global Incidence of Leukemia, by WHO Region, 2022-2050

Table 3 : Global Incidence of Hodgkin Lymphoma, by WHO Region, 2022–2050

Table 4 : Global Incidence of Non-Hodgkin Lymphoma, by WHO Region, 2022-2050

Table 5 : Global Incidence of Multiple Myeloma, by WHO Region, 2022-2050

Table 6 : Patents Held by Oxford Biomedica, 2021–Present

Table 7 : Selected Patents Held by Lonza, 2021–Present

Table 8 : Patents Held by Regenixbio, 2021-Present

Table 9 : Selected Clinical Trials, by Viral Vector Type

Table 10 : Global Market for Viral Vector and Plasmid DNA Technologies, Through 2028

Table 11 : Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028

Table 12 : Global Market for Plasmid DNA Technology, by Region, Through 2028

Table 13 : Global Market for Viral Vector Technology, by Region, Through 2028

Table 14 : Global Market for Viral Vector and Plasmid DNA Technologies, by End User, Through 2028

Table 15 : Global Market for Viral Vector and Plasmid DNA Technologies in Research Institutes, Through 2028

Table 16 : Global Market for Viral Vector and Plasmid DNA Technologies in Research Institutes, by Region, Through 2028

Table 17 : Global Market for Viral Vector and Plasmid DNA Technologies in Pharmaceutical and Biopharmaceutical Companies, Through 2028

Table 18 : Global Market for Viral Vector and Plasmid DNA Technologies in Pharmaceutical and Biopharmaceutical Companies, by Region, Through 2028

Table 19 : Global Market for Viral Vector and Plasmid DNA Technologies, by Application, Through 2028

Table 20 : Global Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028

Table 21 : Global Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Region, Through 2028

Table 22 : North American Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028

Table 23 : North American Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028

Table 24 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028

Table 25 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028

Table 26 : European Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028

Table 27 : European Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028

Table 28 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028

Table 29 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028

Table 30 : RoW Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028

Table 31 : Global Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028

Table 32 : Global Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Region, Through 2028

Table 33 : North American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028

Table 34 : North American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028

Table 35 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028

Table 36 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028

Table 37 : European Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028

Table 38 : European Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028

Table 39 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028

Table 40 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028

Table 41 : RoW Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028

Table 42 : Global Market for Viral Vector and Plasmid DNA Technologies in Infectious



Diseases, Through 2028

Table 43 : Global Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Region, Through 2028

Table 44 : North American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028

Table 45 : North American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028

Table 46 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028

Table 47 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028

Table 48 : European Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028

Table 49 : European Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028

Table 50 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028

Table 51 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028

Table 52 : RoW Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028

Table 53 : Global Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028

Table 54 : Global Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Region, Through 2028

Table 55 : North American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028

Table 56 : North American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028

Table 57 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028

Table 58 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028

Table 59 : European Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028

Table 60 : European Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028

Table 61 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028

Table 62 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028

Table 63 : RoW Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028

Table 64 : Global Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028

Table 65 : Global Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Region, Through 2028

Table 66 : North American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028

Table 67 : North American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028

Table 68 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028

Table 69 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028

Table 70 : European Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028

Table 71 : European Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028

Table 72 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028

Table 73 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country/Region, Through 2028

Table 74 : RoW Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028

Table 75 : Global Market for Viral Vector and Plasmid DNA Technologies, by Region, Through 2028

Table 76 : North American Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028

Table 77 : North American Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028

Table 78 : Latin American Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028

Table 79 : Latin American Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028

Table 80 : European Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028

Table 81 : European Market for Viral Vector and Plasmid DNA Technologies, by

Country, Through 2028

Table 82 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028

Table 83 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028

Table 84 : RoW Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028

Table 85 : ESG Rankings of Major Companies, 2024\*

Table 86 : Lonza: ESG Performance

Table 87 : Thermo Fisher Scientific Inc.: ESG Performance

Table 88 : Acronyms Used in This Report

Table 89 : Agilent Technologies Inc.: Company Snapshot

Table 90 : Agilent Technologies Inc.: Financial Performance, FY 2021 and 2022

Table 91 : Agilent Technologies Inc.: Product Portfolio

Table 92 : Agilent Technologies Inc.: News/Key Developments, 2023

Table 93 : Bluebird Bio Inc.: Company Snapshot

Table 94 : Bluebird Bio Inc.: Financial Performance, FY 2021 and 2022

Table 95 : Bluebird Bio Inc.: Product Portfolio

Table 96 : Bluebird Bio Inc.: Key News/Developments, 2022

Table 97 : Catalent Inc.: Company Snapshot

Table 98 : Catalent Inc.: Financial Performance, FY 2021 and 2022

Table 99 : Catalent Inc.: Product Portfolio

Table 100 : Catalent Inc.: Key News/Developments, 2021-2024

Table 101 : Danaher Corp.: Company Snapshot

Table 102 : Danaher Corp.: Financial Performance, FY 2021 and 2022

Table 103 : Danaher Corp.: Product Portfolio

Table 104 : Danaher Corp.: News/Key Developments, 2022

Table 105 : Fujifilm Holdings Corp.: Company Snapshot

Table 106 : Fujifilm Holdings Corp.: Financial Performance, FY 2021 and 2022

Table 107 : Fujifilm Holdings Corp.: Product Portfolio

Table 108 : Fujifilm Holdings Corp.: News/Key Developments, 2022

Table 109 : GenScript: Company Snapshot

Table 110 : GenScript: Financial Performance, FY 2021 and 2022

Table 111 : GenScript: Product Portfolio

Table 112 : GenScript: News/Key Developments, 2023

Table 113 : Gilead Sciences Inc.: Company Snapshot

Table 114 : Gilead Sciences Inc.: Financial Performance, FY 2021 and 2022

Table 115 : Gilead Sciences Inc.: Product Portfolio

Table 116 : Gilead Sciences Inc.: News/Key Developments, FY 2021-2022

Table 117 : Lonza: Company Snapshot
Table 118 : Lonza: Financial Performance, FY 2021 and 2022
Table 119 : Lonza: Product Portfolio
Table 120 : Lonza: News/Key Developments, FY 2022
Table 121 : Novartis AG: Company Snapshot
Table 122 : Novartis AG: Financial Performance, FY 2021 and 2022
Table 123 : Novartis AG: Product Portfolio
Table 124 : Novartis AG: News/Key Developments, FY 2022
Table 125 : Oxford Biomedica Plc: Company Snapshot
Table 126 : Oxford Biomedica Plc: Financial Performance, FY 2021 and 2022
Table 127 : Oxford Biomedica Plc: Product Portfolio
Table 128 : Oxford Biomedica Plc: News/Key Developments, FY 2022
Table 129 : PlasmidFactory GmbH: Company Snapshot
Table 130 : PlasmidFactory GmbH: Product Portfolio
Table 131 : Regenxbio Inc.: Company Snapshot
Table 132 : Regenxbio Inc: Financial Performance, FY 2021 and 2022
Table 133 : Regenxbio Inc: Product Portfolio
Table 134 : Regenxbio Inc.: News/Key Developments, FY 2022
Table 135 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 136 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2021 and 2022
Table 137 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 138 : VGXI Inc.: Company Snapshot
Table 139 : VGXI Inc.: Product Portfolio

## List Of Figures

### LIST OF FIGURES

Summary Figure A : Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, 2020-2028

Summary Figure B : Global Market Shares of Viral Vector and Plasmid DNA Technologies, by Product Type, 2022

Figure 1 : Viral Vector and Plasmid DNA Technologies: Market Dynamics

Figure 2 : Approved Cell and Gene Therapy Product Count, 2003 to the Present

Figure 3 : Emerging Trends/Technologies in Viral Vector and Plasmid DNA Technologies

Figure 4 : Global Company Market Shares of Viral Vector and Plasmid DNA Technologies, 2022

Figure 5 : Global Company Market Shares of Viral Vectors, 2022

Figure 6 : Global Company Market Shares of Plasmid DNA, 2022

Figure 7 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2022

Figure 8 : Agilent Technologies Inc.: Revenue Share, by Region, FY 2022

Figure 9 : Catalent Inc.: Revenue Share, by Business Unit, FY 2022

Figure 10 : Catalent Inc.: Revenue Share, by Country/Region, FY 2022

Figure 11 : Danaher Corp.: Revenue Share, by Business Unit, FY 2022

Figure 12 : Danaher Corp.: Revenue Share, by Country/Region, FY 2022

Figure 13 : Fujifilm Holdings Corp.: Revenue Share, by Business Unit, FY 2022

Figure 14 : Fujifilm Holdings Corp.: Revenue Share, by Country/Region, FY 2022

Figure 15 : GenScript: Revenue Share, by Business Unit, FY 2022

Figure 16 : GenScript: Revenue Share, by Country/Region, FY 2022

Figure 17 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2022

Figure 18 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2022

Figure 19 : Lonza: Revenue Share, by Business Unit, FY 2022

Figure 20 : Lonza: Revenue Share, by Country/Region, FY 2022

Figure 21 : Novartis AG: Revenue Share, by Business Unit, FY 2022

Figure 22 : Novartis AG: Revenue Share, by Country/Region, FY 2022

Figure 23 : Oxford Biomedica Plc: Revenue Share, by Business Unit, FY 2022

Figure 24 : Oxford Biomedica Plc: Revenue Share, by Country/Region, FY 2022

Figure 25 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2022

Figure 26 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2022

## I would like to order

Product name: Viral Vector and Plasmid DNA: Technologies and Global Markets

Product link: <https://marketpublishers.com/r/V1BDE97496CEN.html>

Price: US\$ 5,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V1BDE97496CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970